A randomized, controlled trial of nasal phenylephrine in infants hospitalized for bronchiolitis.
OBJECTIVE
To examine the hypothesis that pharmacologic treatment of nasal obstruction, specifically alpha-adrenergic nose drops, will decrease objective signs of respiratory distress in infants with bronchiolitis.


METHODS
Forty-one infants aged 3 weeks to 12 months hospitalized for viral bronchiolitis were enrolled in this double-blinded, placebo-controlled trial of topical 0.5% phenylephrine drops. The primary outcome measure was change in oxygen saturation. Secondary outcomes were changes in respiratory scores and vital signs.


RESULTS
There were no statistical differences in any of the outcome measures between groups. No adverse events were observed. Overall, participants showed an average 1.6 percentage point increase in their oxygen saturations (P = .002) and a 0.5-point improvement in respiratory score (P = .003) over the 30 minutes of the study.


CONCLUSIONS
Topical nasal phenylephrine did not produce significant short-term improvements in clinical status in infants hospitalized for acute bronchiolitis.
Ralston
Shawn
S
Department of Pediatrics, Community Medical Center, Missoula, MT, USA.
Roohi
Mahshid
M
D001990:Bronchiolitis, Viral / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D014663:Nasal Decongestants / Q000494:pharmacology / Q000627:therapeutic use*; D009516:New Mexico; D010101:Oxygen Consumption / Q000187:drug effects; D010656:Phenylephrine / Q000494:pharmacology / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects
D014663:Nasal Decongestants; D010656:Phenylephrine